Interleukin-8, nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy


Erdogan C., TEKİN H., Akar S. , Ekmekci O., DONMA O. , Koldas L., ...Daha Fazla

OPHTHALMIC RESEARCH, cilt.35, ss.251-255, 2003 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 35 Konu: 5
  • Basım Tarihi: 2003
  • Doi Numarası: 10.1159/000072145
  • Dergi Adı: OPHTHALMIC RESEARCH
  • Sayfa Sayıları: ss.251-255

Özet

Abstract
Purpose: To evaluate interleukin-8 (IL-8), nitric oxide
(NO) and glutathione (GSH) profiles in vitreous humor
and blood samples in patients with proliferative diabetic
retinopathy (PDR) and in patients with proliferative vitreoretinopathy (PVR) and to compare the levels with
those of controls. Patients and Methods: NO concentrations were determined by using the Greiss reaction in
plasma and vitreous humor samples. GSH levels were
determined in both blood and vitreous humor samples,
using DTNB, a disulfide chromogen. Vitreous IL-8 were
assayed by ELISA. Twenty-three patients with PDR, 18
patients with PVR and 21 cadavers as the control group
were included in the study. Results: Plasma and vitreous
NO levels were found to be 25.6 B 2.1 and 36.9 B
3.0 Ìmol/l in patients with PDR, 27.0 B 4.7 and 34.3 B
2.9 Ìmol/l in patients with PVR and 17.4 B 2.7 and 15.9 B
1.4 Ìmol/l in controls, respectively. Vitreous humor and
plasma NO levels did not show any statistically significant difference between PDR and PVR groups. However,
the values for vitreous in both groups were significantly
higher than those of controls (p ! 0.0001). Although IL-8
levels in vitreous samples of patients with PDR were not
significantly different (79.6 B 9.7 pg/ml) from those of
patients with PVR (42.2 B 7.3 pg/ml) (p = 0.06), the levels
in both groups were significantly higher than those of
controls (19.0 B 3.9 pg/ml) (p ! 0.0001 and p ! 0.05,
respectively). Blood and vitreous GSH levels were found
to be 5.3 B 0.4 Ìmol/gWHb and 0.58 B 0.16 Ìmol/l in
patients with PDR and 8.4 B 0.5 Ìmol/gWHb and 15.7 B
2.2 Ìmol/l in patients with PVR and 12.0 B 1.1 Ìmol/gWHb
and 0.26 B 0.03 mmol/l in controls, respectively. Vitreous and blood GSH levels were significantly lower in
patients with PDR compared to those with PVR (p !
0.0001 for both). Conclusion: Elevated levels of vitreous
and plasma NO and vitreous IL-8 in PDR and PVR implicate a role for these parameters in the proliferation in
these ocular disorders. GSH concentrations both in vitreous and blood samples of the PVR and PDR patients
were much less than those observed in the control
group. Lower GSH concentrations detected in PDR in
comparison with those in PVR in vitreous humor and to a
lesser degree in blood may play an important role in
pathogenesis of new retinal vessel formation in patients
with PDR. This also suggests that oxidative stress may
be involved in the pathogenesis of PVR and particularly
that of PDR
Purpose: To evaluate interieukin-8 (IL-8), nitric oxide (NO) and glutathione (GSH) profiles in vitreous humor and blood samples in patients with proliferative diabetic retinopathy (PDR) and in patients with proliferative vitreoretinopathy (PVR) and to compare the levels with those of controls. Patients and Methods: NO concentrations were determined by using the Greiss reaction in plasma and vitreous humor samples. GSH levels were determined in both blood and vitreous humor samples, using DTNB, a disulfide chromogen. Vitreous IL-8 were assayed by ELISA. Twenty-three patients with PDR, 18 patients with PVR and 21 cadavers as the control group were included in the study. Results: Plasma and vitreous NO levels were found to be 25.6 +/- 2.1 and 36.9 +/- 3.0 mumol/l in patients with PDR, 27.0 +/- 4.7 and 34.3 +/- 2.9 mumol/l in patients with PVR and 17.4 +/- 2.7 and 15.9 +/- 1.4 mumol/l in controls, respectively. Vitreous humor and plasma NO levels did not show any statistically significant difference between PDR and PVR groups. However, the values for vitreous in both groups were significantly higher than those of controls (p < 0.0001). Although IL-8 levels in vitreous samples of patients with PDR were not significantly different (79.6 +/- 9.7 pg/ml) from those of patients with PVR (42.2 +/- 7.3 pg/ml) (p = 0.06), the levels in both groups were significantly higher than those of controls (19.0 +/- 3.9 pg/ml) (p < 0.0001 and p < 0.05, respectively). Blood and vitreous GSH levels were found to be 5.3 +/- 0.4 mumol/g.Hb and 0.58 +/- 0.16 mumol/l in patients with PDR and 8.4 +/- 0.5 mumol/g.Hb and 15.7 +/- 2.2 mumol/l in patients with PVR and 12.0 +/- 1.1 mumol/g.Hb and 0.26 +/- 0.03 mmol/l in controls, respectively. Vitreous and blood GSH levels were significantly lower in patients with PDR compared to those with PVR (p < 0.0001 for both). Conclusion: Elevated levels of vitreous and plasma NO and vitreous IL-8 in PDR and PVR implicate a role for these parameters in the proliferation in these ocular disorders. GSH concentrations both in vitreous and blood samples of the PVR and PDR patients were much less than those observed in the control group. Lower GSH concentrations detected in PDR in comparison with those in PVR in vitreous humor and to a lesser degree in blood may play an important role in pathogenesis of new retinal vessel formation in patients with PDR. This also suggests that oxidative stress may be involved in the pathogenesis of PVR and particularly that of PDR. Copyright (C) 2003 S. Karger AG, Basel.